Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

This marks Marius Pharmaceuticals' fifth U.S. patent, further reinforcing its leadership in the field of testosterone replacement therapy. The newly allowed patent specifically covers the company's ...

in the United States. Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ...

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, ...

U.S. Rep. Lois Frankel, D-West Palm Beach, criticized the Trump Administration's efforts to close the U.S. Department of ...

Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...

Intra-Cellular Therapies, Inc., a biopharmaceutical company ... primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of ...

NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A ... the Innovative Licensing and Access Pathway (ILAP) with the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively ...